Edwards Lifesciences CEO Michael Mussallem promises to make aggressive moves in defending its territory in the transcatheter aortic valve implantation market.
Medtech titan Edwards Lifesciences (NYSE:EW) is poised for a “wild year” ahead in 2014, and the company is looking to move hard and fast in maintaining its leadership in the transcatheter aortic valve implantation market.
Edwards is expecting to face new TAVI competitors in the U.S. and overseas, and the device maker is ready to defend its territory with a strong offense, chairman & CEO Michael Mussallem told an audience today at the J.P. Morgan Health
